FDA/SEC Communication Will Be “Systematized” In Response To Erbitux

FDA's Good Review Management Practices guidance will formalize communications with SEC regarding potentially misleading statements made by sponsors in the preapproval stage, Acting Commissioner Crawford told the House Energy & Commerce/Oversight Subcommittee Oct. 10